P450XXI (Steroid 21-hydroxylase) Gene Deletions are not Found in Family Studies of Congenital Adrenal Hyperplasia

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 84; no. 16; pp. 5858 - 5862
• Main Authors: Matteson, Karla J., Phillips, John A., Miller, Walter L., Chung, Bon-Chu, Orlando, Pamela J., Frisch, Herwig, Ferrandez, Angel, Burr, Ian M.
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences of the United States of America 01.08.1987; National Acad Sciences
• Subjects: Adrenal Hyperplasia, Congenital - enzymology; Adrenal Hyperplasia, Congenital - genetics; Alleles; Amino Acid Sequence; Base Sequence; Chromosome Deletion; Complementary DNA; Congenital adrenal hyperplasia; Crossovers; Cytochrome P-450 Enzyme System - genetics; DNA; DNA - analysis; Enzymes; Gene conversion; Gene deletion; Haploidy; HLA antigens; Humans; Mutation; Pedigree; Steroid 21-Hydroxylase - genetics; Steroid Hydroxylases - genetics; Steroids
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.84.16.5858

Congenital adrenal hyperplasia (CAH) is a common genetic disorder due to defective 21-hydroxylation of steroid hormones. The human P450XXIA2 gene encodes cytochrome P450c21 [steroid 21-monooxygenase (steroid 21-hydroxylase), EC 1.14.99.10], which mediates 21-hydroxylation. The P450XXIA2 gene may be distinguished from the duplicated P450XXIA1 pseudogene by cleavage with the restriction endonuclease Taq I, with the XXIA2 gene characterized by a 3.7-kilobase (kb) fragment and the XXIA1 pseudogene characterized by a 3.2-kb fragment. Restriction endonuclease mapping by several laboratories has suggested that deletion of the P450XXIA2 gene occurs in about 25% of patients with CAH, as their genomic DNA lacks detectable 3.7-kb Taq I fragments. We have cloned human P450c21 cDNA and used it to study genomic DNA prepared from 51 persons in 10 families, each of which includes 2 or more persons with CAH. After Taq I digestion, apparent deletions are seen in 7 of the 20 alleles of the probands; using EcoRI, apparent deletions are seen in 9 of the 20 alleles. However, the apparently deleted alleles seen with Taq I do not coincide with those seen with EcoRI. Furthermore, studies with Bgl II, EcoRI, Kpn I, and Xba I yield normal patterns with at least two enzymes in all cases. Since all probands yielded normal patterns with at least two of the five enzymes used, we conclude that the P450XXIA2 gene ``deletions'' widely reported in CAH patients probably represent gene conversions, unequal crossovers, or polymorphisms rather than simple gene deletions.